Pharmaceuticals Ltd.


BT is developing novel and advanced products for two major medical indications in multi-hundred million-dollar markets. The Company’s mission is to become a leader in the development of obstetric pharmaceuticals, to improve healthcare delivery for patients, doctors and hospitals, and to provide an attractive return on investment for its shareholders and benefits for its strategic partners. Longer term, the 

Company intends to apply its technology to additional lucrative markets such as veterinary obstetrics and to develop products for more OB/Gyn indications.

BT is further augmented by highly esteemed scientific leaders in obstetrics in Europe and the U.S.: Prof. Robert L. Goldenberg, Co-Director of the Center for Research in Women’s Health at the University of Alabama (UAB) and formerly the Chairman of the Department of Obstetrics and Gynecology; Prof. Phillip Robert Bennett, MD, PhD, FRCOG, a Professor in Obstetrics and Gynaecology at the Imperial College School of Medicine, Institute of Obstetrics; Prof. Emile Papiernik, Chairman of the Department of Obstetrics and Gynecology at the Hôpital Cochin, Paris; and Dr. Joseph Blankstein, the Chairman of the department of obstetrics and Gynecology at Mount Sinai Hospital Medical Center in Chicago, Illinois. [CV’s available upon request.


Various scientific case reports on the use of the Preventerm source molecule report no adverse side effects to the mother or infant

Initial tests of Preventerm have shown a 90% efficacy rate in preventing preterm labor – overwhelmingly more effective than any of the currently available treatment modalities

Preventerm stands to decrease the overall expense of preterm infant health care and will reduce infant mortality as well as post-natal complications considerably

We intend to generate revenue through joint and/or strategic collaborations with large pharmaceutical and biotechnology companies in order to further develop our products, jointly facilitate regulatory approval, and subsequently to bring our products to the global markets

A unique investment opportunity: Patented and patent-pending breakthrough drugs Direct solution to a pressing market need Vast expertise in the OB/Gyn industry Several discrete multi-billion dollar markets Strategic value to large pharmaceutical companies